PMID- 24861045
OWN - NLM
STAT- MEDLINE
DCOM- 20141205
LR  - 20151119
IS  - 1423-0259 (Electronic)
IS  - 0030-3747 (Linking)
VI  - 52
IP  - 1
DP  - 2014
TI  - Fluorescein angiography and spectral-domain optical coherence tomography for 
      monitoring anti-VEGF therapy in myopic choroidal neovascularization.
PG  - 25-31
LID - 10.1159/000358331 [doi]
AB  - AIM: To evaluate the agreement between fluorescein angiography (FA) and 
      spectral-domain optical coherence tomography (SD-OCT) in detecting myopic 
      choroidal neovascularization (CNV) activity during bevacizumab treatment. 
      METHODS: Thirty-four patients with subfoveal myopic CNV were prospectively 
      enrolled. FA and SD-OCT were performed at baseline and at all planned monthly 
      visits. After the first injection, additional treatments were administered 
      following detection of fluid on SD-OCT and/or leakage on FA. kappa-Analysis was 
      performed to examine the agreement between FA and SD-OCT. RESULTS: At baseline, 
      FA and SD-OCT agreed in 26/34 cases (kappa=0.23); sensitivity and specificity were 
      77.4 and 66.7%, respectively. Seven eyes presented leakage on FA with no fluid on 
      SD-OCT, 1 case showed intraretinal fluid on SD-OCT and no leakage on FA. At the 
      1-month examination, specificity and kappa-value improved, and 30/34 cases showed 
      complete concordance. At the 3- and 4-month examinations, a discordance was noted 
      in 6 cases. From the 5-month examination on, a correspondence was achieved in at 
      least 30/34 cases and reached a perfect match in 11 sessions. CONCLUSIONS: Our 
      study confirms the key role of FA in diagnosing myopic CNV. It seems possible 
      there may be a role for SD-OCT in assisting FA to monitor the myopic CNV activity 
      during anti-vascular endothelial growth factor antibody treatment.
CI  - (c) 2014 S. Karger AG, Basel.
FAU - Iacono, Pierluigi
AU  - Iacono P
AD  - G.B. Bietti Foundation for Ophthalmology, Istituto di Ricovero e Cura a Carattere 
      Scientifico, Rome, Italy.
FAU - Battaglia Parodi, Maurizio
AU  - Battaglia Parodi M
FAU - Papayannis, Alexandros
AU  - Papayannis A
FAU - Kontadakis, Stylianos
AU  - Kontadakis S
FAU - Da Pozzo, Stefano
AU  - Da Pozzo S
FAU - Cascavilla, Maria Lucia
AU  - Cascavilla ML
FAU - La Spina, Carlo
AU  - La Spina C
FAU - Varano, Monica
AU  - Varano M
FAU - Bandello, Francesco
AU  - Bandello F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20140524
PL  - Switzerland
TA  - Ophthalmic Res
JT  - Ophthalmic research
JID - 0267442
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Bevacizumab
MH  - Choroidal Neovascularization/*diagnosis/drug therapy
MH  - Drug Monitoring
MH  - Female
MH  - *Fluorescein Angiography
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Myopia, Degenerative/*diagnosis/drug therapy
MH  - Ophthalmoscopy
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - *Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors
EDAT- 2014/05/28 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/05/28 06:00
PHST- 2013/09/04 00:00 [received]
PHST- 2014/01/03 00:00 [accepted]
PHST- 2014/05/28 06:00 [entrez]
PHST- 2014/05/28 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 000358331 [pii]
AID - 10.1159/000358331 [doi]
PST - ppublish
SO  - Ophthalmic Res. 2014;52(1):25-31. doi: 10.1159/000358331. Epub 2014 May 24.